|
|
 |
|
Viewing report
|
|
 |
 |
Icact 2001: Highlights of Trial Results, Discussions and Commercial Implications
Datamonitor, Feb 2001
Already established as the treatment of choice for metastatic breast cancer, strong results from US trials have seen the taxanes surge into the adjuvant setting. Within Europe however, the taxanes are unlikely to be incorporated into treatment patterns for localized disease before the results of key clinical trials become available. This brief reviews the major trial releases and topics of discussion from the International Conference of Anti-Cancer Treatment, 6-9 February 2001, including current issues in the treatment of solid tumor and hematological malignancies, as well as updates on the progress of novel agents, such as Iressa, Faslodex and rhuMAb Vegf, through clinical trials.
Customers who bought this item also bought
Drug Transporters and ADME: Pharmacological and Commercial Implications
Successfully Marketing Clinical Trial Results
Anti-hypertensives: Landmark clinical trial update - Commercial assessment of Charm, Comet, Ephesus and Europa
Proactive Results - The Diabetes Trial That Could Have Been
H1 2001 Results: Financial Results of the Top 12 Pharmaceutical Companies
2001 Results: Financial Results of the Top 16 Pharmaceutical and Biotechnology Companies
Optimizing the Clinical Trial Process: Strategies to Reduce Costs and Increase Quality
Optimizing the Clinical Trial Process: Strategies to Reduce Costs and Increase Quality
|
 |
|
|